Company & Sponsor Intelligence
Intra-Cellular Therapies, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed2
Countries1
Therapeutic footprint
alzheimersanxietyparkinsons
Indexed studies
NCT06701903Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
anxiety · United StatesPHASE2
anxiety · United StatesPHASE2
NCT02078310Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
alzheimers · United StatesPHASE1, PHASE2
alzheimers · United StatesPHASE1, PHASE2
NCT05766813Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →